大肠杆菌在生物制药生产中的作用
1Kazım Karabekir Vocational School, Department of Medical Services and Techniques, Environmental Health Program, Karamanoğlu Mehmetbey University, Karaman, Turkey.
Biotechnology and applied biochemistry
|September 9, 2024
概括
大肠杆菌是生产胰岛素等生物制药的关键宿主. 这项研究回顾了已批准的大肠杆菌衍生药物,强调了它们的治疗应用和开发.
科学领域:
- 微生物学 微生物学
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 大肠杆菌 (E. coli) 通过重组DNA技术彻底改变了生物制药生产.
- 在大肠杆菌中开发复合胰岛素标志着糖尿病治疗的新时代.
- 许多由大肠杆菌生产的生物制药已经获得了对各种人类疾病的监管批准.
研究的目的:
- 审查由大肠杆菌生产并批准用于治疗的生物制药.
- 将这些生物制药按类型 (,荷尔蒙,酶等) 分类. ) 的情况.
- 详细介绍它们的治疗应用,生产时间表和开发者.
主要方法:
- 关于使用大肠杆菌生产的批准生物制药的文献审查.
- 根据治疗类和蛋白质类型进行分类.
- 对批准状态,说明和生产历史的分析.
主要成果:
- 大肠杆菌是生产各种生物制药的多功能宿主,包括,荷尔蒙,酶,融合蛋白,抗体碎片和疫苗.
- 经批准的大肠杆菌衍生药物治疗广泛的人类疾病.
- 该研究详细介绍了这些重要的治疗剂的开发和应用.
结论:
- 尽管存在诸如缺乏翻译后修改等局限性,但大肠杆菌仍然是生物制药制造成本高效和高产量的宿主.
- 大肠杆菌在生产拯救生命的药物的作用继续扩大.
- 本综述提供了对大肠杆菌对现代医学贡献的全面概述.
相关概念视频
Stringent Response in E. coli
Bacterial growth is closely tied to nutrient availability, with cells proliferating exponentially under favorable conditions and entering a stationary phase when resources become scarce. This transition is mediated by a regulatory mechanism known as the stringent response, which allows bacteria to adapt to nutrient deprivation by modulating gene expression and metabolic activity.During nutrient scarcity, intracellular amino acid levels decline. It results in the accumulation of uncharged tRNAs...
Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...


